Anti-MeV Non-structural protei

abinScience, founded in 2023 in Strasbourg, France, is committed to developing and producing high-quality life science reagents. Rooted in one of Europe’s leading hubs for scientific innovation, abinScience empowers global research through reliable, efficient experimental solutions. Guided by the vision of “Empowering Bioscience Discovery,” we support scientists worldwide in advancing the frontiers of bioscience.

Technology and Innovation

Relying on the global leading position in antibody and protein research and more than 20 years of industry experience of its parent company ProteoGenix since 2003, abinScience has inherited advanced technologies and high-quality standards. In particular, the XtenCHO™ system developed by ProteoGenix, which has two modes of transient expression and stable expression, has been widely recognized as a core technology to improve the efficiency of protein production, providing a solid foundation for abinScience's product quality.

Product categories and application fields.

Main products.
10000+ high-activity proteins.
15000+ antibody series products:
Classic monoclonal antibody.
Monoclonal antibody
Internal control antibody, labeled antibody.
High-quality phosphorylation antibodies.
Highly specific nanobodies and small molecule antibodies.
Functional antibodies in vivo.
Low-background flow cytometry antibodies.
DNA/RNA antibodies and PEG antibodies.
1000+ reagent kit series products.
Large-scale packaging customization services: We offer personalized antibody design, protein production, molecular optimization, and experimental development services.

Application field

Infectious disease research: including viruses, superbugs, parasites, etc.
Neuroscience research: Supporting research on neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.
Immunology research: Covers the research needs of immune activation, inhibition, and allergies and abnormal reactions.
Oncology research: Supporting the development of tumor biology and anti-tumor drugs.